Quarterly Earnings

Pfizer offers timing for a split; earnings dip in Q2

By

Pfizer said 2017 is the earliest the firm could split up. Meanwhile, sales dropped 7% year-on-year.

Forest sees quarterly and annual sales sink

By

Generic Lexapro sapped company sales for the fiscal quarter and year, ended March 31.

Oncology lifts Roche's Q1, Lucentis finds new fans

Oncology lifts Roche's Q1, Lucentis finds new fans

By

Roche's oncology trifecta of Herceptin, Avastin and mabThera/Rituxan buoyed quarterly sales. Devices and diagnostics sales were solid, if less impressive.

Company news: BMS goes over the patent cliff

Sales of Bristol-Myers Squibb's Plavix plunged 96% in the third quarter over the same period last year, contributing mightily to an overall 30% drop in sales of the company's products for the quarter, to $3.7 billion.

Amgen's Prolia, Enbrel get sales overhauls, DTC

Amgen's Prolia, Enbrel get sales overhauls, DTC

Sales of Amgen's Prolia are set to rise after a "soft" quarter, thanks to a sales force overhaul and an impending return to TV advertising, the company said in a third quarter results call.

Lilly sales dip 11% as diabetes drugs feel payer pressure

By

Price increases and belt-tightening helped prop up Eli Lilly's third quarter, but loss of formulary positioning on two key products hurt sales.

J&J, Roche reports lifted by strong drug sales

J&J, Roche reports lifted by strong drug sales

By

J&J and Roche reported modest sales increases, with pharma sales providing a boost for J&J and oncology driving Roche's nine- month performance.

Biogen Idec sees revenue surge on MS drug sales

Biogen Idec sees revenue surge on MS drug sales

By

Biogen Idec saw revenue rise 18% in the second quarter to $1.4 billion amid strong sales of Avonex, with a host of promising late-stage pipeline products waiting in the wings.

Abbott, on track for split, posts strong Q2 numbers

By

Abbott Labs reported strong second quarter sales that, though mitigated by an unfavorable exchange rate, cheered analysts and investors, with muscular growth in Humira sales a high point.

J&J reports sales slip as Weldon exits

J&J reports sales slip as Weldon exits

By

Johnson & Johnson reported a 0.2% drop in overall sales for the first quarter of 2012, compared with the same period the year before, as CEO Bill Weldon prepared to hand over the reins of the company.


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.

Email Newsletters